Compile Data Set for Download or QSAR
maximum 50k data
Found 123 Enz. Inhib. hit(s) with all data for entry = 11746
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM50599226(CHEMBL5201062 | US11866405, Example 100)
Affinity DataIC50: <0.0300nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM50599222(CHEMBL5190644 | US11866405, Example 12)
Affinity DataIC50:  0.100nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643825(US11866405, Example 95)
Affinity DataIC50:  0.200nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM50599223(CHEMBL5202941 | US11866405, Example 23)
Affinity DataIC50:  0.200nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643809(US11866405, Example 87)
Affinity DataIC50:  0.200nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643768(US11866405, Example 4)
Affinity DataIC50: <0.300nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643785(US11866405, Example 75)
Affinity DataIC50:  0.300nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643820(US11866405, Example 30 | US11866405, Example 31)
Affinity DataIC50: <0.300nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643823(US11866405, Example 94)
Affinity DataIC50:  0.300nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643834(US11866405, Example 37)
Affinity DataIC50:  0.300nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643867(US11866405, Example 116)
Affinity DataIC50:  0.300nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM50599227(CHEMBL5204583 | US11866405, Example 117)
Affinity DataIC50:  0.300nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643875(US11866405, Example 120 | US11866405, Example 121 ...)
Affinity DataIC50:  0.300nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643849(US11866405, Example 107 | US11866405, Example 108)
Affinity DataIC50:  0.400nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643837(US11866405, Example 101)
Affinity DataIC50: <0.400nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643821(US11866405, Example 93)
Affinity DataIC50:  0.400nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643803(US11866405, Example 84)
Affinity DataIC50:  0.400nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643779(US11866405, Example 72)
Affinity DataIC50:  0.400nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643775(US11866405, Example 70)
Affinity DataIC50:  0.400nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643770(US11866405, Example 5)
Affinity DataIC50:  0.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643773(US11866405, Example 69)
Affinity DataIC50:  0.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643827(US11866405, Example 96)
Affinity DataIC50:  0.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643816(US11866405, Example 28 | US11866405, Example 29)
Affinity DataIC50:  0.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643873(US11866405, Example 119)
Affinity DataIC50:  0.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643763(US11866405, Example 64 | US11866405, Example 65)
Affinity DataIC50: <0.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643854(US11866405, Example 47)
Affinity DataIC50:  0.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643790(US11866405, Example 15)
Affinity DataIC50:  0.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643767(US11866405, Example 66 | US11866405, Example 67)
Affinity DataIC50: <0.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643847(US11866405, Example 106)
Affinity DataIC50:  0.600nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643868(US11866405, Example 54)
Affinity DataIC50:  0.600nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643843(US11866405, Example 104 | US11866405, Example 109)
Affinity DataIC50:  0.600nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643796(US11866405, Example 18 | US11866405, Example 19)
Affinity DataIC50: <0.600nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643792(US11866405, Example 16)
Affinity DataIC50:  0.600nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643852(US11866405, Example 46)
Affinity DataIC50:  0.600nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643831(US11866405, Example 98)
Affinity DataIC50:  0.600nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643841(US11866405, Example 103)
Affinity DataIC50:  0.600nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643829(US11866405, Example 97)
Affinity DataIC50:  0.700nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643802(US11866405, Example 21)
Affinity DataIC50:  0.700nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643794(US11866405, Example 17 | US11866405, Example 20)
Affinity DataIC50:  0.700nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643789(US11866405, Example 77)
Affinity DataIC50:  0.700nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643772(US11866405, Example 6)
Affinity DataIC50:  0.700nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643839(US11866405, Example 102)
Affinity DataIC50:  0.700nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643879(US11866405, Example 122)
Affinity DataIC50:  0.700nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643870(US11866405, Example 55)
Affinity DataIC50:  0.700nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643863(US11866405, Example 114)
Affinity DataIC50:  0.700nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643861(US11866405, Example 113)
Affinity DataIC50:  0.700nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643859(US11866405, Example 112)
Affinity DataIC50:  0.700nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643856(US11866405, Example 48)
Affinity DataIC50:  0.700nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643846(US11866405, Example 43 | US11866405, Example 44)
Affinity DataIC50:  0.800nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643880(US11866405, Example 60)
Affinity DataIC50:  0.800nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 123 total ) | Next | Last >>
Jump to: